Trial Profile
Biosimilar Retacrit (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology; Non-interventional, Observational, Prospective Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Epoetin zeta (Primary)
- Indications Chemotherapy-induced anaemia
- Focus Therapeutic Use
- Acronyms ORHEO
- Sponsors Hospira
- 14 Apr 2014 New trial record